Scarica l'app Stockscreener
989.12
0.41%
4.04
Pre-mercato:
980.03
-9.09
-0.92%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$985.08
Aprire:
$991.98
Volume 24 ore:
2.28M
Relative Volume:
0.74
Capitalizzazione di mercato:
$883.28B
Reddito:
$65.18B
Utile/perdita netta:
$20.64B
Rapporto P/E:
43.79
EPS:
22.5894
Flusso di cassa netto:
$5.96B
1 W Prestazione:
-1.91%
1M Prestazione:
-4.89%
6M Prestazione:
+29.35%
1 anno Prestazione:
+21.59%
Intervallo 1D:
$975.51
$998.17
Intervallo di 1 settimana:
$973.16
$1,012.00
Portata 52W:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
989.12 | 883.28B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.19 | 586.06B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
221.45 | 391.56B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
192.01 | 297.77B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.87 | 295.52B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Defensive Sectors: Are Utilities, Staples, and Health Care Signaling Trouble? - Investing.com
Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans - Insider Monkey
RBC Capital Markets Pounds the Table on Eli Lilly Stock (LLY) as Share Price Falls - TipRanks
Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? - The Motley Fool
Eli Lilly and Company reports new data point to significant itch relief for pediatric eczema - Traders Union
Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth - AOL.com
LLY: Eli Lilly's Upcoming Weight Loss Pill Faces New Competition - GuruFocus
Structure Weight-Loss Pill Results Rival Novo, Lilly Treatments - Bloomberg.com
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly
Hilltop Holdings Inc. Acquires 8,154 Shares of Eli Lilly and Company $LLY - MarketBeat
Holocene Advisors LP Has $114.14 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Lilly’s Ebglyss meets endpoints in pediatric dermatitis trial By Investing.com - Investing.com India
Lilly’s Ebglyss meets endpoints in pediatric dermatitis trial - Investing.com
Eczema drug EBGLYSS helped more kids reach clear skin in Phase 3 trial - Stock Titan
Fred Alger Management LLC Has $73.09 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Elevation Point Wealth Partners LLC Boosts Holdings in Eli Lilly and Company $LLY - MarketBeat
CSM Advisors LLC Has $8.37 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Calydon Capital Sells 2,787 Shares of Eli Lilly and Company $LLY - MarketBeat
Algert Global LLC Boosts Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Co Stock (ISIN: US5324571083) Faces Volatility Amid Strong GLP-1 Momentum and Analyst - AD HOC NEWS
Eli Lilly executive to speak at BBJ manufacturing summit - The Business Journals
Eli Lilly (LLY) to Invest $3 Billion in China Over the Next Decade, Reuters Reports - Insider Monkey
Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand - MarketBeat
Clear Street Group Inc. Takes $30.48 Million Position in Eli Lilly and Company - National Today
Azimuth Capital Trims Stake in Eli Lilly - National Today
Clear Street Group Inc. Takes $30.48 Million Position in Eli Lilly and Company $LLY - MarketBeat
Ameriprise Financial Inc. Has $2.27 Billion Stake in Eli Lilly and Company $LLY - MarketBeat
The Pill War Heats Up: Novo Relies On Wegovy To Reclaim Leadership From Eli Lilly - Emirates 24|7
Eli Lilly and Company $LLY Shares Sold by Texas Capital Bancshares Inc TX - MarketBeat
Roche’s breast cancer failure; BioNTech co-founders to depart; Eli Lilly’s quest to stay on top; and more - Endpoints News
Harvest Fund Management Trims Eli Lilly Stake - National Today
LLY Stock Quote Price and Forecast - CNN
Harvest Fund Management Co. Ltd Sells 4,467 Shares of Eli Lilly and Company $LLY - MarketBeat
Dodge & Cox Sells 1,573 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline - AOL.com
Eli Lilly Stock Pulls Back from January Peak as Valuation Pressures Mount - AD HOC NEWS
Is Eli Lilly's Weight Loss Empire in Trouble? - AOL.com
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12 - AOL.com
Stock Quote & Chart - Eli Lilly
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm - FinancialContent
The Real Reason Eli Lilly Is Pouring $3 Billion Into China - MarketBeat
3,120 Shares in Eli Lilly and Company $LLY Purchased by Te Ahumairangi Investment Management Ltd - MarketBeat
Jim Cramer on Eli Lilly: “We’re Not Budging, We’d Buy More If It Really Got Hit” - Insider Monkey
Kroger Shares Rise, Pharmacies Add Eli Lilly Zepbound KwikPenKroger (NYSE:KR), Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Boosts Chinese Manufacturing Investments - advancedmanufacturing.org
Kroger Says Eli Lilly's Zepbound KwikPen Now Available at Participating Pharmacies - marketscreener.com
Kroger to Offer Eli Lilly's Zepbound KwikPen With Expanded Access to Savings Program - 富途牛牛
Novo regained weight loss footing in the pill arena — but Lilly is coming - Pharma Voice
Form Health Joins the Lilly Employer Connect Platform - Business Wire
Martingale Asset Management Reduces Stake in Eli Lilly - National Today
Quadrature Capital Ltd Buys New Shares in Eli Lilly and Company $LLY - MarketBeat
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.69%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):